This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n12http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F14%3A00077947%21RIV15-MSM-14110___/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F14%3A00077947%21RIV15-MSM-14110___
rdf:type
skos:Concept n18:Vysledek
dcterms:description
Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively.
dcterms:title
Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience
skos:prefLabel
Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience
skos:notation
RIV/00216224:14110/14:00077947!RIV15-MSM-14110___
n3:aktivita
n7:P n7:I
n3:aktivity
I, P(ED1.100/02/0123), P(ED2.1.00/03.0101)
n3:cisloPeriodika
6
n3:dodaniDat
n17:2015
n3:domaciTvurceVysledku
n5:7720823 n5:7668635 n5:1306642 n5:1419374 n5:3140075 n5:7721706
n3:druhVysledku
n11:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n9:predkladatel
n3:idSjednocenehoVysledku
50857
n3:idVysledku
RIV/00216224:14110/14:00077947
n3:jazykVysledku
n10:eng
n3:klicovaSlova
adjuvant chemoradiation; gastric cancer; early toxicity; late toxicity; survival outcomes
n3:klicoveSlovo
n8:survival%20outcomes n8:gastric%20cancer n8:late%20toxicity n8:adjuvant%20chemoradiation n8:early%20toxicity
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[A648218524EF]
n3:nazevZdroje
Neoplasma
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
10
n3:projekt
n12:ED1.100%2F02%2F0123 n12:ED2.1.00%2F03.0101
n3:rokUplatneniVysledku
n17:2014
n3:svazekPeriodika
61
n3:tvurceVysledku
Budíková, Marie Pospíšil, Petr Slávik, Marek Slavikova, M. Gombosova, J. Navrátilová, P. Burkoň, Petr Šlampa, Pavel Dvorakova, E. Kazda, Tomáš
n3:wos
000345950900013
s:issn
0028-2685
s:numberOfPages
8
n14:doi
10.4149/neo_2014_090
n16:organizacniJednotka
14110